BioCardia Inc - ESG Rating & Company Profile powered by AI
Browse to the bottom of this webpage for potential risks for BioCardia Inc based on industry, geography and marketcap. Alternative companies in the rating industry group for BioCardia Inc are shown. The analysis of BioCardia Inc incorporates data from across the internet as well as from public disclosures by BioCardia Inc.
BioCardia Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.1; made up of an environmental score of 5.3, social score of 0.0 and governance score of 4.0.
3.1
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1299 | Active Fine Chemicals Ltd | 3.2 | Medium |
| 1299 | Yuhan Corp | 3.2 | Medium |
| 1309 | BioCardia Inc | 3.1 | Medium |
| 1309 | Champions Oncology Inc | 3.1 | Medium |
| 1309 | IBEX Technologies Inc | 3.1 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does BioCardia Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes BioCardia Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes BioCardia Inc report the average age of the workforce?
Sign up for free to unlockDoes BioCardia Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes BioCardia Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes BioCardia Inc disclose cybersecurity risks?
Sign up for free to unlockDoes BioCardia Inc offer flexible work?
Sign up for free to unlockDoes BioCardia Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes BioCardia Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes BioCardia Inc conduct supply chain audits?
Sign up for free to unlockDoes BioCardia Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes BioCardia Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes BioCardia Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes BioCardia Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes BioCardia Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes BioCardia Inc disclose water use targets?
Sign up for free to unlockDoes BioCardia Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid BioCardia Inc have a product recall in the last two years?
Sign up for free to unlockDoes BioCardia Inc disclose incidents of discrimination?
Sign up for free to unlockDoes BioCardia Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas BioCardia Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes BioCardia Inc disclose parental leave metrics?
Sign up for free to unlockDoes BioCardia Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes BioCardia Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes BioCardia Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes BioCardia Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes BioCardia Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes BioCardia Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs BioCardia Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes BioCardia Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes BioCardia Inc disclose its waste policy?
Sign up for free to unlockDoes BioCardia Inc report according to TCFD requirements?
Sign up for free to unlockDoes BioCardia Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes BioCardia Inc disclose energy use targets?
Sign up for free to unlockDoes BioCardia Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes BioCardia Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for BioCardia Inc
These potential risks are based on the size, segment and geographies of the company.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.